MJStocks Tuesday Update- 8/28/2018!
GT Biopharma Announces Initiation of OXS-1550 In Combination With A Multi-Billion Dollar Oncology Drug
This morning GT Biopharma (GTBP) made a major announcement that it has initiated a combination trial of its OXS-1550 with a multi-billion dollar oncology drug, owned by a Major Pharmaceutical Company. What is the multi-billion dollar oncology drug? It’s called ibrutinib, which was developed by Pharmacyclics up to Phase II, then partnered with Johnson & Johnson…but what could be the biggest piece of information with this drug is that Pharmacyclics was acquired by AbbVie who just reported net sales of ibrutinib of $2.573 Billion, an Increase of 40.5%! What could this mean for GT Biopharma and its OXS-1550?
Click Here For More Details & Read Today’s Full Release
Marijuana Stocks: A Clinical Stage Company Presents Growth Opportunities
It’s clear that companies like Gilead or Merck don’t have any plans on slowing down the M&A trend anytime soon. Gilead’s CEO has even said that the company is “quite interested in things that would augment cellular therapy.”
For this reason many investors have started to search for “the next early clinical stage” opportunity. What if we told you that some of the most experienced people in the biotechnology sector have made a move to join a company that, right now, is quietly beginning to develop major breakthroughs for things like pain management and cancer?
Full Report
Is This What Canada’s Legalization Means For Pot Stocks?
A financial boom not seen since the dot-com mania of the late 1990s has taken over Canada. The legalization of recreational marijuana, scheduled for this fall, is not only a momentous social event, but also a rare opportunity for to be in on the birth of what they hope will become a multibillion-dollar industry.
Click Here For Full Release
Disclaimer: Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC and GT Biopharma, Midam has been paid $200,000 from the company and ZERO shares of GT Biopharma Inc. for a duration beginning July 16, 2018 and ending August 16, 2018. Midam Ventures has been paid an additional $200k by GT Biopharma and has extended its marketing period through Sept 16, 2018. We may buy or sell additional shares of (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC and Beleave Inc., Midam has been paid $200,000 from the company and ZERO shares of Beleave Inc. for a duration of 6 weeks beginning June 18, 2018 and ending July 31, 2018 NOW EXTENDED TO 8/31/2018. We may buy or sell additional shares of (BLEVF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
